SirTlab Corporation
Genetic Treatment for Age-related Diseases
Company Overview
Snapshot
Founded in January 2012 by Boaz Misholi, SirTlab Corporation operates with 1–10 employees. The company has raised $1.53 million across three funding rounds. In May 2025, SirTlab Corporation secured equity crowdfunding from PipelBiz.
Business overview
SirTlab Corporation is a Health Tech & Life Sciences company focused on developing genetic treatments for age-related diseases, particularly severe liver conditions. The company's core technology centers on restoring SIRT6 expression using its patented SIRT6-mRNA-LNP2 for liver-specific expression. This approach is based on extensive research into sirtuin proteins, which are key regulators for cellular health. SirTlab aims to develop agents for treating non-alcoholic steatohepatitis (NASH), other forms of cirrhosis, metabolic syndrome, acetaminophen toxicity, and broader diseases of aging, targeting the pharmaceuticals market.
Strategic signal
In June 2022, SirTlab Corporation appointed Michael G. Kauffman as Co-Chairman of the Board of Directors and Chief Medical Officer. This strategic leadership addition, bringing significant biotechnology industry experience and a track record in cancer drug approvals, signals the company's intent to accelerate the advancement of its novel class of agents, particularly its lead program focused on sirtuin 6 (SIRT6) for severe liver diseases and longevity.
Log in to access full profile ›Company Intelligence Q&A
- What is SirTlab Corporation's primary focus?
- SirTlab Corporation is focused on developing genetic treatments for age-related diseases, specifically by restoring SIRT6 expression for severe liver diseases and other conditions of aging.
- When was SirTlab Corporation founded?
- SirTlab Corporation was founded in January 2012.
- Who is the founder of SirTlab Corporation?
- Boaz Misholi is the founder of SirTlab Corporation.
- What significant leadership appointment did SirTlab Corporation make?
- In June 2022, SirTlab Corporation appointed Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer. This appointment is expected to advance the company's novel class of agents.